iRhythm Technologies (NASDAQ:IRTC) Rating Lowered to "Hold" at Wall Street Zen

Key Points

• Wall Street Zen downgraded iRhythm Technologies to “Hold” from “Buy,” despite the broader analyst consensus remaining “Moderate Buy” with a $179.36 target price.
• iRhythm reported strong quarterly results, posting $0.58 in earnings per share versus expectations for a $0.04 loss, while revenue increased 20.1% year over year to $224.17 million.
• The company agreed to acquire VitalConnect for $287.5 million, expanding its wearable cardiac-monitoring portfolio, and projected 2026 revenue of $880 million to $890 million with a 13%–14% adjusted EBITDA margin target.

iRhythm Technologies (NASDAQ:IRTC - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research note issued to investors on Saturday.

A number of other brokerages have also recently commented on IRTC. Citigroup upped their price target on shares of iRhythm Technologies from $155.00 to $157.00 and gave the company a "buy" rating in a research report on Monday, May 4th. Stephens began coverage on iRhythm Technologies in a research report on Thursday, July 23rd. They issued an "overweight" rating and a $160.00 price objective for the company. Canaccord Genuity Group dropped their price objective on iRhythm Technologies from $180.00 to $152.00 and set a "buy" rating on the stock in a research note on Monday, June 1st. Bank of America cut their target price on iRhythm Technologies from $225.00 to $180.00 and set a "buy" rating on the stock in a research report on Monday, May 18th. Finally, Truist Financial decreased their target price on iRhythm Technologies from $174.00 to $160.00 and set a "buy" rating for the company in a research note on Thursday, July 16th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, iRhythm Technologies presently has a consensus rating of "Moderate Buy" and a consensus target price of $179.36.

iRhythm Technologies Stock Down 0.2%

Shares of NASDAQ IRTC opened at $127.84 on Friday. The company's 50 day moving average price is $115.03 and its 200-day moving average price is $124.57. The company has a debt-to-equity ratio of 4.03, a quick ratio of 4.98 and a current ratio of 5.17. iRhythm Technologies has a 52-week low of $100.85 and a 52-week high of $212.00. The company has a market capitalization of $4.20 billion, a P/E ratio of -297.30 and a beta of 1.30.

iRhythm Technologies (NASDAQ:IRTC - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.58 earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.62. iRhythm Technologies had a negative net margin of 1.69% and a positive return on equity of 10.81%. The company had revenue of $224.17 million during the quarter, compared to analysts' expectations of $219.30 million. During the same period in the prior year, the company posted ($0.32) earnings per share. iRhythm Technologies's revenue for the quarter was up 20.1% compared to the same quarter last year. Equities analysts forecast that iRhythm Technologies will post 0.13 earnings per share for the current year.

Insider Transactions at iRhythm Technologies

In related news, Director Abhijit Y. Talwalkar purchased 5,312 shares of iRhythm Technologies stock in a transaction on Monday, May 11th. The stock was acquired at an average cost of $10.71 per share, for a total transaction of $56,891.52. Following the completion of the acquisition, the director owned 25,611 shares of the company's stock, valued at $274,293.81. This trade represents a 26.17% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.98% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On iRhythm Technologies

Institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. increased its position in iRhythm Technologies by 2.2% in the 4th quarter. Vanguard Group Inc. now owns 3,310,519 shares of the company's stock valued at $587,418,000 after buying an additional 70,420 shares in the last quarter. RTW Investments LP acquired a new position in iRhythm Technologies during the 4th quarter worth approximately $209,732,000. Geode Capital Management LLC boosted its holdings in iRhythm Technologies by 8.6% in the fourth quarter. Geode Capital Management LLC now owns 858,405 shares of the company's stock worth $152,337,000 after acquiring an additional 68,301 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in iRhythm Technologies by 45.6% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 829,862 shares of the company's stock worth $147,251,000 after acquiring an additional 259,800 shares in the last quarter. Finally, Millennium Management LLC grew its stake in iRhythm Technologies by 197.4% in the fourth quarter. Millennium Management LLC now owns 826,376 shares of the company's stock valued at $146,632,000 after acquiring an additional 548,519 shares during the period.

Key Stories Impacting iRhythm Technologies

Here are the key news stories impacting iRhythm Technologies this week:

• Positive Sentiment: Strong Q2 results: iRhythm reported adjusted earnings of $0.58 per share, versus the consensus estimate of a $0.04 loss, while revenue rose 20.1% year over year to $224.17 million, exceeding the $219.30 million estimate. iRhythm Holdings Tops Q2 Earnings and Revenue Estimates
• Positive Sentiment: VitalConnect acquisition expands addressable market: The company agreed to acquire privately held VitalConnect for $287.5 million. The deal would add wearable biosensors and broaden iRhythm’s cardiac-monitoring platform across ambulatory, inpatient and hospital-to-home settings, with closing expected by year-end. iRhythm to Buy VitalConnect for $287.5 Million
• Positive Sentiment: Raised financial ambitions: iRhythm projected 2026 revenue of $880 million to $890 million and is targeting a 13% to 14% adjusted EBITDA margin, signaling confidence in continued growth and operating leverage. iRhythm Outlines 2026 Revenue Outlook
• Neutral Sentiment: Legal overhang may be reduced: A federal court approved a proposed class-action settlement involving purchasers of iRhythm common stock. The settlement could reduce litigation uncertainty, although the articles do not specify its financial impact. Proposed iRhythm Class-Action Settlement
• Negative Sentiment: Lower valuation support from Wells Fargo: Wells Fargo reduced its price target from $180 to $168, though it maintained an “overweight” rating and still implied substantial upside. The cut may have contributed to near-term caution.

About iRhythm Technologies

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company's flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm's digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source